Felker is a professor of medicine in the Duke University School of Medicine and the director of cardiovascular and metabolism research at the Duke Clinical Research Institute. Dr. Felker will discuss TARGET-HF-DM, a pragmatic trial that tested the effectiveness of a mobile health intervention to improve physical activity and medication adherence among patients with heart failure and diabetes mellitus.
According to the World Health Organization, vaccine hesitancy refers to the delay in acceptance of, or refusal of, vaccines despite availability of vaccination services.
Vaccine hesitancy is complex and context specific, varying across time, place, and vaccines. It is influenced by factors such as complacency, convenience, and confidence. Hesitancy occurs on a continuum, from acceptance of all vaccines, to acceptance but doubt, to vaccine delayers, refusers, and deniers.
HERO-TOGETHER is a prospective, observational, multicenter cohort study of 20,000 adult U.S. healthcare workers who received a COVID-19 vaccine within the past 60 days. The study will collect data from participants that includes their experience with receiving the vaccine, medical history, unexpected medical care, safety events, and quality of life.
Discussion Themes
There is no universal best practice to address vaccine hesitancy in all its contexts. Locally tailored and multicomponent approaches will be needed.
How has the political environment influenced the hesitancy around receiving the COVID-19 vaccine?
What are your approaches to evaluating vaccine safety? What about safety for women during child-bearing years?
A new chapter in the Living Textbook provides expert advice for investigators considering using mobile technologies in pragmatic clinical trials. The chapter outlines many of the possibilities, advantages, and challenges associated with mobile health (mHealth) interventions, with a particular focus on design and evaluation of these programs in pragmatic clinical trials.
“We will illustrate many design and evaluation challenges, culminating with a discussion of how these considerations influence the ongoing development of the Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications (Nudge) project.”—Real-World Evidence: Mobile Health (mHealth)
In this Friday’s PCT Grand Rounds, Dr. Michael Felker of Duke University will present “A Randomized Controlled Trial of a Mobile Health Intervention in Heart Failure and Diabetes: Lessons Learned.” The Grand Rounds session will be held on Friday, November 18, 2022, at 1:00 pm eastern.